Knight Therapeutics バランスシートの健全性

財務の健全性基準チェック /56

Knight Therapeuticsの総株主資本はCA$773.9M 、総負債はCA$51.7Mで、負債比率は6.7%となります。総資産と総負債はそれぞれCA$962.3MとCA$188.4Mです。 Knight Therapeuticsの EBIT はCA$10.3Mで、利息カバレッジ比率277.7です。現金および短期投資はCA$172.3Mです。

主要情報

6.7%

負債資本比率

CA$51.65m

負債

インタレスト・カバレッジ・レシオ	277.7x
現金	CA$172.32m
エクイティ	CA$773.91m
負債合計	CA$188.39m
総資産	CA$962.29m

財務の健全性に関する最新情報

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03

Recent updates

Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 09

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02

財務状況分析

短期負債: GUDの短期資産 ( CA$397.6M ) が短期負債 ( CA$118.2M ) を超えています。

長期負債: GUDの短期資産 ( CA$397.6M ) が長期負債 ( CA$70.2M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: GUD総負債よりも多くの現金を保有しています。

負債の削減: GUDの負債対資本比率は、過去 5 年間で0%から6.7%に増加しました。

債務返済能力: GUDの負債は営業キャッシュフローによって十分にカバーされています ( 102.1% )。

インタレストカバレッジ: GUDの負債に対する利息支払いは EBIT ( 277.7 x coverage) によって十分にカバーされています。

Knight Therapeutics バランスシートの健全性

財務の健全性 基準チェック /56

主要情報

財務の健全性に関する最新情報

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Recent updates

Knight Therapeutics Inc. Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder

President recently bought CA$103k worth of stock

Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: CA$0.001 (vs CA$0.09 in 3Q 2023)

Knight Therapeutics Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Knight Therapeutics Inc. Revises Earnings Guidance for the Year 2024

Knight Therapeutics Inc. to Report Q2, 2024 Results on Aug 08, 2024

Independent Director recently sold CA$148k worth of stock

Executive Chairman exercised options to buy CA$543k worth of stock.

Price target increased by 7.3% to CA$7.24

Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024

First quarter 2024 earnings released: CA$0.045 loss per share (vs CA$0.035 loss in 1Q 2023)

Knight Therapeutics Inc. to Report Q1, 2024 Results on May 09, 2024

President exercised options to buy CA$309k worth of stock.

Full year 2023 earnings released: CA$0.16 loss per share (vs CA$0.26 loss in FY 2022)

Knight Therapeutics Inc. to Report Q4, 2023 Results on Mar 21, 2024

Knight Therapeutics Inc., Annual General Meeting, May 08, 2024

Knight Therapeutics Inc. Announces Regulatory Submission of Fostamatinib in Brazil

Knight Therapeutics Inc. Announces Launch of Bijuva® in Canada

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q3, 2023 Results on Nov 09, 2023

Knight Therapeutics Inc. Announces CMED Price Approval of Minjuvi (tafasitamab) in Brazil

United Medical Ltd. Announces Regulatory Submission of Pemigatinib in Brazil

Executive Chairman recently bought CA$111k worth of stock

Knight Therapeutics Inc. Updates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q2, 2023 Results on Aug 10, 2023

Insufficient new directors

President recently bought CA$95k worth of stock

Knight Therapeutics Inc. Updates Revenue Guidance for the Fiscal 2023

First quarter 2023 earnings released: CA$0.035 loss per share (vs CA$0.16 loss in 1Q 2022)

Knight Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 309%

Price target decreased by 12% to CA$6.30

Knight Therapeutics Inc. Announces Relaunch of AKYNZEO in Canada

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. Reports Impairment of Intangible Assets for the Third Quarter Ended September 30, 2022

Knight Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Knight Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Executive Chairman recently bought CA$135k worth of stock

Executive Chairman recently bought CA$104k worth of stock

Executive Chairman recently bought CA$207k worth of stock

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2022

Knight Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to CA$6.86

Independent Director recently bought CA$89k worth of stock

President recently bought CA$104k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Knight Therapeutics Inc., Annual General Meeting, May 11, 2022

Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia

Executive Chairman recently bought CA$102k worth of stock

Executive Chairman recently bought CA$102k worth of stock

Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia

President recently bought CA$82k worth of stock

Executive Chairman recently bought CA$105k worth of stock

Executive Chairman recently bought CA$95k worth of stock

Third quarter 2021 earnings released: CA$0.07 loss per share (vs CA$0.14 profit in 3Q 2020)

High number of new directors

High number of new directors

Executive Chairman recently bought CA$105k worth of stock

CEO & Director recently bought CA$202k worth of stock

Consensus EPS estimates increase to CA$0.28

Second quarter 2021 earnings released: EPS CA$0.23 (vs CA$0.13 in 2Q 2020)

CEO & Director recently bought CA$94k worth of stock

財務の健全性基準チェック /56